Germany-headquartered CNS drug specialist Neuraxpharm today revealed that UK health technology assessor the National ...

New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

The Subject Expert Committee (SEC), under the Central Drugs Standard Control Organisation (CDSCO), has recommended approval of additional indication of US-based Bristol-Myers Squibb's anti-cancer drug ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces that the National Institute for ...

Trastuzumab deruxtecan is a targeted drug used to treat certain types of cancer: breast cancer, gastric or gastroesophageal ...